MRNS250117C1000
- 0.05
- 0.000.00%
Marinus Pharmaceuticals Newsroom
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Express News | Marinus Pharmaceuticals Inc - on Dec 6, Receives Nasdaq Notice for Minimum Bid Price Deficiency
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Hold Rating on Marinus Pharmaceuticals Amid Strategic Uncertainty and TRUST-TSC Study Setbacks
RBC Capital Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating, Cuts Target Price to $1
TD Cowen Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Marinus Pharmaceuticals GAAP EPS of -$0.42 In-line, Revenue of $8.54M Misses by $0.81M
Marinus Pharmaceuticals | 8-K: Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Express News | Marinus Pharmaceuticals Inc Q3 Shr View $-0.41, Rev View $9.4 Mln -- LSEG IBES Data
Marinus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Marinus Pharmaceuticals Narrows 2024 Net Pdt Rev Guidance to $33M to $34M >MRNS
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q3 Revenue $8.5M
Express News | Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Press Release: Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Marinus Pharmaceuticals 3Q Loss/Shr 42c >MRNS
12 Health Care Stocks Moving In Monday's Pre-Market Session